<DOC>
	<DOC>NCT01281657</DOC>
	<brief_summary>The purpose of this observational study is to collect long-term data on safety and effectiveness of fingolimod, particularly including clinical disease and patient outcome related parameters such as relapse and disability, in patients who have participated in prior trials within the fingolimod clinical development program. Furthermore, this study explores the incidence of selected safety related outcomes of fingolimod treatment during follow-up visits within the context of routine medical practice.</brief_summary>
	<brief_title>Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients who are prescribed fingolimod as part of their routine medical care Patients who have participated in a prior fingolimod clinical trials Restrictions regarding the use of fingolimod while pregnant or nursing in accordance with the local prescribing label Any patient who has prematurely discontinued from the previous fingolimod trial Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Fingolimod</keyword>
	<keyword>FTY720</keyword>
	<keyword>Relapsing forms of multiple sclerosis</keyword>
	<keyword>Multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>